share_log
Reuters ·  Aug 16 17:45
Phanes Therapeutics' PT217 Receives Orphan Drug Designation for Neuroendocrine Carcinoma From the FDA
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment
      翻译: